Core Viewpoint - Harvard Bioscience, Inc. is restructuring its production operations to streamline processes and reduce long-term costs, which has positively impacted its stock price [1] Facility Changes - The company will close its Holliston, Massachusetts plant and shift U.S. production to its Minneapolis, Minnesota hub, with some operations moving to Germany, Sweden, and the U.K. [2] - CEO John Duke emphasized that the reorganization will enhance flexibility and leverage scale and expertise across different sites [2] Financial Impact - Management anticipates approximately $3 million in savings by 2027, with annual savings expected to reach about $4 million starting in 2028, driven by lower overhead, fewer SKUs, and improved asset utilization [3] Workforce and Execution - The company plans to reconfigure roles across its operations and has established a phased transition plan to ensure order fulfillment and product quality during the consolidation [4] - The Holliston facility will remain operational until 2026 to support customers, with the goal of completing the consolidation by the first quarter of 2027 [4] - Transition-related costs may increase expenses until mid-2027 [4] Stock Performance - Harvard Bioscience shares increased by 0.63% to $0.54 in premarket trading, although the stock has declined over 69% in the past year [5]